Inhibrx Inc (INBX)
34.06
-0.03
(-0.09%)
USD |
NASDAQ |
Apr 26, 16:00
34.05
-0.01
(-0.03%)
After-Hours: 20:00
Inhibrx Cash from Financing (Quarterly): 0.86M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.86M |
| September 30, 2023 | 199.89M |
| June 30, 2023 | 0.854M |
| March 31, 2023 | 0.356M |
| December 31, 2022 | 158.66M |
| September 30, 2022 | 0.506M |
| June 30, 2022 | 60.16M |
| March 31, 2022 | 39.22M |
| December 31, 2021 | 41.48M |
| September 30, 2021 | 0.82M |
| June 30, 2021 | 40.48M |
| Date | Value |
|---|---|
| March 31, 2021 | 0.988M |
| December 31, 2020 | 17.00M |
| September 30, 2020 | 136.22M |
| June 30, 2020 | 16.88M |
| March 31, 2020 | -3.633M |
| December 31, 2019 | -0.439M |
| September 30, 2019 | -1.885M |
| June 30, 2019 | 35.86M |
| March 31, 2019 | 9.795M |
| June 30, 2018 | 7.135M |
| March 31, 2018 | -1.755M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.633M
Minimum
Mar 2020
199.89M
Maximum
Sep 2023
39.17M
Average
16.88M
Median
Jun 2020
Cash from Financing (Quarterly) Benchmarks
| Axonics Inc | 0.578M |
| NovaBay Pharmaceuticals Inc | -0.026M |
| Palatin Technologies Inc | 4.974M |
| iBio Inc | 4.005M |
| Theriva Biologics Inc | -1.457M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -56.82M |
| Cash from Investing (Quarterly) | -3.442M |
| Free Cash Flow | -197.90M |
| Free Cash Flow Per Share (Quarterly) | -1.114 |
| Free Cash Flow to Equity (Quarterly) | -61.51M |
| Free Cash Flow to Firm (Quarterly) | -56.74M |
| Free Cash Flow Yield | -12.33% |